A Randomized, Double-blind, Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) Doses of GSK3494245 in Healthy Participants
Latest Information Update: 26 Feb 2024
At a glance
- Drugs GSK 3494245 (Primary)
- Indications Leishmaniasis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 26 Feb 2024 Status changed from recruiting to completed.
- 17 Jul 2023 Status changed from suspended to recruiting.
- 17 Jul 2023 Planned End Date changed from 27 Apr 2023 to 14 Jun 2024.